

## AMENDMENTS TO THE CLAIMS

1-10. (cancelled)

11. (withdrawn) A recombinant adenovirus containing an expression vector comprising P972 gene and a promoter operably linked to the P972 gene, wherein said adenovirus is capable of infecting mammalian cells.

12. (withdrawn) The recombinant adenovirus of claim 11, wherein the adenovirus is AdP972 and has Accession No. KCTC 0806BP.

13. (withdrawn) The recombinant adenovirus of claim 11, wherein the P972 gene is wild-type human P972 cDNA.

14. (withdrawn) A mammalian cell transformed with the adenovirus of claim 11.

15. (withdrawn) The mammalian cell of claim 14, wherein the cell is a human cell.

16. (withdrawn) The mammalian cell of claim 15 wherein the cell is a cancer cell.

17. (withdrawn) The human cell of claim 15, wherein the cell is a cancer cell.

18. (withdrawn) The human cell of claim 15, wherein the cancer cell is selected from a breast cancer cell, a colon cancer cell or a cervical cancer cell.

19. (currently amended) A method of treating cancer in a mammal in need thereof, comprising directly administering directly to cancer cells of the mammal an effective amount of a recombinant adenovirus containing an expression vector comprising P972 gene and a promoter operably linked to the P972 gene, wherein said adenovirus is capable of infecting mammalian cells.

20. (previously presented) A method of treating cancer in a mammal in need thereof, comprising directly administering to the mammal a recombinant adenovirus, wherein the adenovirus is AdP972 and has Accession No. KCTC 0806BP.

21. (previously presented) The method of claim 19, wherein the cancer is selected from the group consisting of cervical cancer, breast cancer, and colon cancer.

22 - 37. (cancelled)